ADC	Antibody–drug conjugate
ald-MMAF	MMAF with aldehyde group
ALT	Alanine aminotransferase
AST	Aspartate aminotransferase
AUC	area under the curve
B-N-F	Brentuximab-MMAF conjugate synthesized via NTERM conjugation
BSA	Bovine serum albumin
(C)	Conjugated antibody concentration
CL	Clearance
DAR	Drug-to-antibody ratio
DLT	Dose-limiting toxicity
ELISA	Enzyme-linked immunosorbent assay
FBS	Fetal bovine serum
HER2	Human epidermal growth factor receptor 2
HL	Hodgkin lymphoma
HPLC	High-performance liquid chromatography
HRP	Horseradish peroxidase
LC	Liquid chromatography
mc-MMAF	MMAF with maleimide group
MED	Minimum efficacious dose
MMAF	Monomethyl auristatin F
mpk	mg per kg
MS	Mass spectroscopy
MTD	Maximum tolerable dose
NTERM	N-terminal conjugation through amine bond formation by reductive alkylation reaction
ORR	Objective response rate
PBS	Phosphate-buffered saline
PK	Pharmacokinetic
PFS	Progression-free survival
SD	Sprague Dawley
SMCC	Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate
SPR	Surface plasmon resonance
SH-MMAF	MMAF with thiol group
(T)	Total antibody concentration
T-C-F	Trastuzumab-MMAF conjugate synthesized thiol-conjugation
TFA	Trifluoroacetic acid
T-K-F	Trastuzumab-MMAF conjugate synthesized via lysine conjugation
T-N-F	Trastuzumab-MMAF conjugate synthesized via NTERM conjugation